JP2023052910A5 - - Google Patents

Download PDF

Info

Publication number
JP2023052910A5
JP2023052910A5 JP2023015725A JP2023015725A JP2023052910A5 JP 2023052910 A5 JP2023052910 A5 JP 2023052910A5 JP 2023015725 A JP2023015725 A JP 2023015725A JP 2023015725 A JP2023015725 A JP 2023015725A JP 2023052910 A5 JP2023052910 A5 JP 2023052910A5
Authority
JP
Japan
Prior art keywords
residue
group
formula
salt
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023015725A
Other languages
English (en)
Japanese (ja)
Other versions
JP7708133B2 (ja
JP2023052910A (ja
Filing date
Publication date
Priority claimed from PCT/JP2018/017345 external-priority patent/WO2018199337A1/ja
Application filed filed Critical
Publication of JP2023052910A publication Critical patent/JP2023052910A/ja
Publication of JP2023052910A5 publication Critical patent/JP2023052910A5/ja
Priority to JP2025113314A priority Critical patent/JP7754361B2/ja
Application granted granted Critical
Publication of JP7708133B2 publication Critical patent/JP7708133B2/ja
Priority to JP2025166056A priority patent/JP2025185050A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023015725A 2017-04-28 2023-02-03 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 Active JP7708133B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2025113314A JP7754361B2 (ja) 2017-04-28 2025-07-03 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
JP2025166056A JP2025185050A (ja) 2017-04-28 2025-10-02 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2017090679 2017-04-28
JP2017090679 2017-04-28
PCT/JP2018/017345 WO2018199337A1 (ja) 2017-04-28 2018-04-27 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
JP2019514691A JP7222347B2 (ja) 2017-04-28 2018-04-27 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019514691A Division JP7222347B2 (ja) 2017-04-28 2018-04-27 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025113314A Division JP7754361B2 (ja) 2017-04-28 2025-07-03 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩

Publications (3)

Publication Number Publication Date
JP2023052910A JP2023052910A (ja) 2023-04-12
JP2023052910A5 true JP2023052910A5 (enExample) 2023-04-25
JP7708133B2 JP7708133B2 (ja) 2025-07-15

Family

ID=63918939

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019514691A Active JP7222347B2 (ja) 2017-04-28 2018-04-27 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
JP2023015725A Active JP7708133B2 (ja) 2017-04-28 2023-02-03 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
JP2025113314A Active JP7754361B2 (ja) 2017-04-28 2025-07-03 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
JP2025166056A Pending JP2025185050A (ja) 2017-04-28 2025-10-02 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019514691A Active JP7222347B2 (ja) 2017-04-28 2018-04-27 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2025113314A Active JP7754361B2 (ja) 2017-04-28 2025-07-03 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
JP2025166056A Pending JP2025185050A (ja) 2017-04-28 2025-10-02 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩

Country Status (8)

Country Link
US (2) US12024549B2 (enExample)
EP (2) EP4603507A3 (enExample)
JP (4) JP7222347B2 (enExample)
KR (3) KR20240046307A (enExample)
CN (1) CN110637036A (enExample)
AU (2) AU2018259856B2 (enExample)
CA (1) CA3061467A1 (enExample)
WO (1) WO2018199337A1 (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7291395B2 (ja) * 2017-06-16 2023-06-15 国立大学法人 鹿児島大学 ＩｇＧ結合ペプチド、及び該ペプチドによる抗体の特異的修飾
EP3808760A4 (en) * 2018-06-14 2022-10-05 Ajinomoto Co., Inc. COMPOUND WITH AFFINITY FOR ANTIBODY, CLEAVAGE SITE AND REACTIVE GROUP OR SALT THEREOF
JPWO2019240288A1 (ja) * 2018-06-14 2021-07-26 味の素株式会社 抗体に対する親和性物質、および生体直交性官能基を有する化合物またはその塩
JPWO2020090979A1 (ja) * 2018-10-31 2021-09-24 味の素株式会社 抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
CN113631539B (zh) * 2019-01-23 2025-08-15 阿比蒂斯有限公司 用于制备抗体-载荷部分偶联物的化合物及其用途
WO2020184944A1 (ko) * 2019-03-08 2020-09-17 앱티스 주식회사 위치특이적 항체 콘쥬게이션 및 이의 구체예로서의 항체-약물 콘쥬게이트
CA3155284A1 (en) 2019-10-24 2021-04-29 Yuji Ito Method for producing monovalent ccap product
AU2020388383A1 (en) * 2019-11-18 2022-03-31 Kleo Pharmaceuticals, Inc. Directed conjugation technologies
US20230046947A1 (en) * 2019-12-03 2023-02-16 Debiopharm Research & Manufacturing S.A. Reactive conjugates
WO2022078566A1 (en) * 2020-10-12 2022-04-21 Debiopharm Research & Manufacturing S.A. Reactive conjugates
CA3208290A1 (en) 2021-01-18 2022-07-21 Ajinomoto Co., Inc. Compound or salt thereof, and antibody obtained by using the same
CN116829573A (zh) * 2021-01-18 2023-09-29 味之素株式会社 化合物或其盐、及由它们得到的抗体
WO2022191283A1 (ja) 2021-03-11 2022-09-15 味の素株式会社 化合物またはその塩、およびそれらにより得られる抗体
JPWO2022196675A1 (enExample) 2021-03-16 2022-09-22
CN113292633B (zh) * 2021-05-13 2023-08-29 中国科学技术大学 可见光诱导甘氨酸衍生物的肼化修饰方法
KR20240012380A (ko) * 2021-05-17 2024-01-29 바이오하벤 테라퓨틱스 리미티드 지향 접합 기술용 제제 및 접합 생성물
JP2024521092A (ja) * 2021-05-19 2024-05-28 バイオヘイブン・セラピューティクス・リミテッド 細胞傷害性薬剤を送達するためのｍａｔｅｓ技術を使用する抗体薬物コンジュゲート
EP4349373A1 (en) 2021-06-01 2024-04-10 Ajinomoto Co., Inc. Conjugate of antibody and functional substance or salt of said conjugate, and compound for use in production of said conjugate or salt of said compound
CA3224147A1 (en) 2021-07-09 2023-01-12 Vijaya Raghavan PATTABIRAMAN Antibody conjugates and manufacture thereof
WO2023281479A1 (en) 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Checkpoint inhibitors conjugated to il-2, and uses thereof
WO2023281483A1 (en) 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Modified tnf-antibodies and uses thereof
US20230201365A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Modified cd20 antibodies and uses thereof
JP2024529297A (ja) 2021-07-09 2024-08-06 ブライト ピーク セラピューティクス エージー Ｉｌ－２を有するチェックポイント阻害剤のコンジュゲート及びその使用
CA3231257A1 (en) 2021-09-08 2023-03-16 Yuji Ito Compound, salt of compound, antibody modification reagent, method for producing modified antibody, and modified antibody
WO2023054714A1 (ja) 2021-09-30 2023-04-06 味の素株式会社 抗体および機能性物質の位置選択的なコンジュゲートまたはその塩、ならびにその製造に用いられる抗体誘導体および化合物またはそれらの塩
KR20240073035A (ko) 2021-09-30 2024-05-24 아지노모토 가부시키가이샤 항체 및 기능성 물질의 컨쥬게이트 또는 그 염, 및 그 제조에 사용되는 항체 유도체 및 화합물 또는 그 염
EP4482531A1 (en) 2022-02-23 2025-01-01 Bright Peak Therapeutics AG Immune antigen specific il-18 immunocytokines and uses thereof
US20250163101A1 (en) 2022-03-04 2025-05-22 AbTis Co., Ltd. Method for increasing production yield of antibody-drug conjugate by using thiol-reactive additive
CN116836235A (zh) * 2022-03-25 2023-10-03 中国科学院上海药物研究所 亲和片段导向的可裂解片段，其设计、合成及在制备定点药物偶联物中的应用
JPWO2023234416A1 (enExample) * 2022-06-02 2023-12-07
KR20240125071A (ko) 2022-11-01 2024-08-19 앱티스 주식회사 Fc 결합성 유닛을 포함하는 화합물 및 이를 이용하여 제조된 컨쥬게이트
US20240417436A1 (en) 2023-01-11 2024-12-19 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
US20240424127A1 (en) 2023-01-11 2024-12-26 Bright Peak Therapeutics Ag Il-7 polypeptides, immunocytokines comprising same, and uses thereof
EP4682173A1 (en) * 2023-03-15 2026-01-21 Kagoshima University Method for producing radiolabeled antibody, radiolabeled antibody, and radioactive medicine
KR20250172615A (ko) 2023-04-04 2025-12-09 아지노모토 가부시키가이샤 항체 및 기능성 물질의 컨쥬게이트, 항체 유도체 및 화합물, 또는 그것들의 염
JPWO2024210178A1 (enExample) 2023-04-05 2024-10-10
US20250188166A1 (en) 2023-08-23 2025-06-12 Bright Peak Therapeutics Ag Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof
WO2025041101A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
WO2025041102A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Targeted immune activation with il-18 immunocytokines
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250144234A1 (en) 2023-11-02 2025-05-08 Capstan Therapeutics Inc. RNA for In vivo Transfection with Increased Expression
US20250332281A2 (en) 2023-12-15 2025-10-30 Capstan Therapeutics, Inc. Humanized anti-cd8 antibodies and uses thereof
WO2025158412A1 (en) 2024-01-26 2025-07-31 Biohaven Therapeutics Ltd. BIFUNCTIONAL DEGRADERS OF IgG4 IMMUNOGLOBULINS
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025181697A1 (en) 2024-02-26 2025-09-04 Biohaven Therapeutics Ltd. Bifunctional degraders of anti-pla2r antibody
WO2025210538A1 (en) 2024-04-02 2025-10-09 Biohaven Therapeutics Ltd. Bifunctional degraders
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89220A (en) 1988-02-11 1994-02-27 Bristol Myers Squibb Co Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
JP2000503639A (ja) 1995-12-22 2000-03-28 ブリストル―マイヤーズ スクイブ カンパニー 分枝ヒドラゾンのリンカー類
JP3825502B2 (ja) * 1996-06-11 2006-09-27 日本油脂株式会社 修飾蛋白質の製造法及びコンタクトレンズ用汚れ除去剤
ATE218892T1 (de) * 1997-11-07 2002-06-15 Conjuchem Inc Affinitätsmarkierer für menschliches serum albumin
EP1757311B1 (en) 1999-12-24 2009-02-11 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
DE60030323T2 (de) 1999-12-24 2007-10-11 Genentech, Inc., South San Francisco Verfahren und verbindungen zur verlängerung der halbwertzeiten bei der ausscheidung von biowirksamen verbindungen
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
DE10162773A1 (de) 2001-12-20 2003-07-10 Knf Flodos Ag Sursee Dosierpumpe
CA2802205C (en) 2002-07-31 2016-01-19 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
EP1560599A1 (en) 2002-11-14 2005-08-10 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
CN103394083B (zh) 2003-11-06 2017-07-18 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
NZ550934A (en) 2004-05-19 2010-05-28 Medarex Inc Chemical linkers and conjugates thereof
JP5167473B2 (ja) 2005-03-03 2013-03-21 コヴェックス・テクノロジーズ・アイルランド・リミテッド 抗血管新生化合物
US8637656B2 (en) 2005-07-05 2014-01-28 Ribomic Inc. Nucleic acid capable of binding to immunoglobulin G and use thereof
EP1989547A1 (en) 2006-02-28 2008-11-12 Medical Research Council Targeted iron oxide nanoparticles
EP2093287A4 (en) 2006-11-02 2010-04-21 Univ Kagoshima PEPTIDE BINDER IGG
WO2008056346A2 (en) 2006-11-10 2008-05-15 Covx Technologies Ireland Limited Anti-angiogenic compounds
WO2011121560A2 (en) * 2010-03-31 2011-10-06 Universite De Geneve Stabilized antibody preparations and uses thereof
CN103890174B (zh) 2011-08-24 2015-12-23 大塚化学株式会社 IgG结合性肽及利用其检测和纯化IgG的方法
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
CA2916202C (en) * 2013-06-24 2019-07-02 Hanwha Chemical Corporation Antibody-drug conjugate having improved stability and use thereof
CN113332449B (zh) * 2014-06-12 2023-12-22 石药集团巨石生物制药有限公司 酶法制备同质的抗体-药物缀合物
US20160000933A1 (en) * 2014-07-01 2016-01-07 Andrei POLUKHTIN Conjugated biological molecules and their preparation
JP5827769B1 (ja) 2015-03-27 2015-12-02 義徳 川窪 掃除装置
US10227383B2 (en) * 2015-05-20 2019-03-12 Kagoshima University Specific modification of antibody with IgG-binding peptide
TWI703158B (zh) * 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
BR112018012388A2 (pt) 2015-12-18 2018-12-04 Eisai R&D Management Co., Ltd. imunoglobulinas conjugadas de lisina terminal-c
JP7020403B2 (ja) * 2016-05-02 2022-02-16 味の素株式会社 アジド基含有Ｆｃタンパク質
CN109071606A (zh) * 2016-06-13 2018-12-21 国立大学法人鹿儿岛大学 利用IgG结合肽的位点特异性放射性同位素标记抗体

Similar Documents

Publication Publication Date Title
JP2023052910A5 (enExample)
JP7417432B2 (ja) 新規リンカー、その製造方法およびその応用
Sato et al. Ligand-directed selective protein modification based on local single-electron-transfer catalysis.
Guichard et al. Antigenic mimicry of natural L-peptides with retro-inverso-peptidomimetics.
AU2018259856B2 (en) Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof
US20210040177A1 (en) Multi-Specific Molecules
US20090234105A1 (en) Construction of a Multivalent SCFV Through Alkyne-Azide 1,3-Dipolar Cycloaddition
US6821529B2 (en) Oligo(ethylene glycoll)-terminated 1,2-dithiolanes and their conjugates useful for preparing self-assembled monolayers
EP0093652B1 (fr) Toxine synthétique ST, son procédé de préparation et son application comme agent vaccinant
JP2005539067A5 (enExample)
US6403324B1 (en) Affinity labeling libraries with tagged leaving group
JP2020506685A5 (enExample)
EP0527954A4 (en) Molecular recognition units
IL100811A (en) Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock
JP2021516959A (ja) アルケンホスホノチオレートまたはアルキンホスホノチオレートおよびアルケンホスホネートまたはアルキンホスホネートとの化学選択的チオールコンジュゲーション
JPWO2022191283A5 (enExample)
CA2162157A1 (en) Polyoxime compounds and their preparation
JPH03501622A (ja) 蛋白誘導体及びその調製法
WO2001013114A1 (fr) Composes synthetiques portant deux epitopes pour immunodosages
RS64205B1 (sr) Antitelo koje sadrži c-terminalnu ekstenziju lakog lanca koja sadrži glutamin, njegovi konjugati, i postupci i primene
EP0964871B1 (fr) Composes synthetiques biepitopiques utilisables comme etalons dans les dosages biologiques de la troponine i
EP0920443B1 (en) Activated peptides and conjugates
IE910750A1 (en) A monoclonal antibody against complexed and noncomplexed complexing agents for removing heavy metals from aqueous solutions and for analysis
Hussein et al. Synthesis of nickel-chelating fluorinated lipids for protein monolayer crystallizations
CN101918841B (zh) 肽-脂构造及其在诊断和治疗用途中的应用